News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neose Technologies, Inc. (NTEC) Announces Discontinuation of NE-180 Program; Job Cuts


1/29/2008 4:17:14 PM

HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (NasdaqGM: NTEC) today announced the discontinuation of further development of NE-180 (GlycoPEGylated erythropoietin) based on an evaluation of commercial prospects and the likelihood of entering into a timely collaboration for the compound in the context of increased safety concerns in the erythropoiesis-stimulating agent (ESA) category. NE-180 is the Company’s product candidate for the treatment of anemia in patients with chronic kidney disease and cancer patients receiving chemotherapy. The decision to discontinue development is not due to any safety or efficacy concerns about NE-180. Read articles below.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES